BMY

Bristol-Myers Squibb Company | Cotação de Ações

Última atualização17/04/2025, 17:00:02

PreçoUS$ 49,23

Variação (dia)-US$ 0,13 (-0.26%)▼

Min. 52 SemanasUS$ 39,35

Máx. 52 SemanasUS$ 63,33

Capitalização de mercado--

Endereço: Route 206 & Province Line Road, Princeton, NJ, 08543

Telefone: 609 252 4621

Funcionários: 34.100

Bristol-Myers Squibb CompanyBMY

US$ 49,23

- 0,130,26%

17/04/2025 17:00:02

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 49,23

Valor de mercado--

AberturaUS$ 49,71

Preço máximoUS$ 50,09

Preço mínimoUS$ 49,06

VolumeUS$ 14 mi

Fechamento anteriorUS$ 49,36

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Ações relacionadas

Merck & Co., Inc.

MRK ▼1.53% | US$ 96,39

Eli Lilly and Company

LLY ▲7.31% | US$ 733,03

Abbott Laboratories

ABT ▲2.50% | US$ 115,98

AbbVie Inc.

ABBV ▲0.75% | US$ 172,31

Amgen Inc.

AMGN ▲2.74% | US$ 274,85

Acesse a Documentação para uma compreensão detalhada da nossa plataforma

Explore a Documentação para uma compreensão detalhada de como utilizar efetivamente nossa plataforma para análise de investimentos. Oferecemos recursos abrangentes para orientar investidores, desde iniciantes até experientes, na navegação por nossa plataforma.

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.